Co-administration with CYP3A4 inhibitors

Lumeva · Episodic migraine

MI-2026-0628RoutineClosedWithin SLA

FAFatima Al-SayedMedical Information Lead

Received: 07 Sept 2026, 09:20 UTC
Channel: Email
Requestor type: Pharmacist
Country / region / team: Germany · Europe · MI Europe
Category: Drug interaction
Response type: Standard response
Owner: FAFatima Al-Sayed
Due: 12 Sept 2026, 09:20 UTC
Responded: 08 Sept 2026, 11:20 UTC
Quality review: Not required
Related insight: —
Related standard response: SR-LMV-007 · Co-administration with CYP3A4 inhibitors (v3)

Workflow

12-stage inquiry workflow (PRD §16). Advancing records an audit event.

Current stageClosedDemo action — not persisted

Routine: 120 h target · Routine 120 h / Urgent 48 h / Critical 24 h

SLA hours

120

Elapsed

26 h

to response

Remaining

94 h

22%

07 Sept 2026, 09:20 UTC
Received via Email
Pharmacist · Germany
07 Sept 2026, 09:20 UTC
Triage and assignment
Urgency Routine · assigned to MI Europe
08 Sept 2026, 11:20 UTC
Response sent
Standard response · quality review not required
12 Sept 2026, 09:20 UTC
SLA due (120 h)

Demo — drafts are not persisted

AI suggestion available for non-safety inquiries

Draft response

No audit events for this record

Create, update, approve and export events appear here with user, timestamp, previous and new values.

Data lineage: MI inquiry platform (IRMS, INT-05) · received 07 Sept 2026 · hourly sync.